Patents by Inventor Bjoern Chapuy

Bjoern Chapuy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240117440
    Abstract: The invention provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.
    Type: Application
    Filed: September 15, 2023
    Publication date: April 11, 2024
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Bjoern CHAPUY, Donald STEWART, Tim WOOD, Margaret SHIPP, Gad GETZ, Mark MURAKAMI, Lee LAWTON, Andrew DUNFORD, Kirsty WIENAND
  • COMPOSITIONS AND METHODS FOR CHARACTERIZING LYMPHOMA AND RELATED CONDITIONS
    Publication number: 20240052428
    Abstract: The invention provides compositions and methods useful in characterizing and/or treating classical Hodgkin's Lymphoma and/or primary mediastinal B-cell lymphoma (PMBL). In embodiments, the characterization is carried out using a biological sample comprising circulating tumor DNA (ctDNA) from a subject.
    Type: Application
    Filed: September 15, 2023
    Publication date: February 15, 2024
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Margaret SHIPP, Gad GETZ, Bjoern CHAPUY, Kirsty WIENAND, Donald STEWART, Andrew DUNFORD, Mark MURAKAMI, Lee LAWTON
  • Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
    Patent number: 11446309
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 20, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
  • COMBINATION THERAPY FOR CANCER USING BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITORS
    Publication number: 20210100813
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Application
    Filed: July 16, 2020
    Publication date: April 8, 2021
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok Kin Wong, Zhao Chen
  • CLASSIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20200270702
    Abstract: Disclosed are methods and reagents for diagnosis, classification and treatment of DLBCL and subtypes thereof by means of gene expression profiling. Provided herein is a gene expression signature for use in obtaining diagnostic information for DLBCL and subtypes thereof. Aspects of the present disclosure relate to use of gene expression signature corresponding to particular subtype for classification of a sample from a subject and stratification of a subject for subtype-targeted clinical trial. Also provided herein is a computer based classification model for use in the methods disclosed herein.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 27, 2020
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Stefano MONTI, Daniel GUSENLEITNER, Margaret SHIPP, Bjoern CHAPUY
  • THERAPEUTIC TREATMENT OF SELECT DIFFUSE LARGE B CELL LYMPHOMAS EXHIBITING DISTINCT PATHOGENIC MECHANISMS AND OUTCOMES
    Publication number: 20190292602
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of DLBCL. In particular, the instant disclosure provides a DLBCL classifier that has identified at least five distinct classes of DLBCL cancer, each of which possesses distinct pathogenic mechanisms and outcomes. The instant classifier identifies preferred therapeutic options (including combination therapies) for each such class of DLBCL cancer.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Bjoern Chapuy, Margaret Shipp, Chip Stewart, Andrew Dunford, Gad Getz
  • Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
    Patent number: 9890429
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 13, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub
  • CLASSIFICATION OF MYC-DRIVEN B-CELL LYMPHOMAS
    Publication number: 20170029904
    Abstract: Methods for diagnosing Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) based on a diagnostic score, as well as determining MYC activity levels and selecting treatments based on a MYC activity score.
    Type: Application
    Filed: April 7, 2015
    Publication date: February 2, 2017
    Inventors: Scott J. Rodig, Christopher Daniel Carey, Margaret A. Shipp, Stefano Monti, Daniel Gusenleitner, Bjoern Chapuy
  • COMBINATION THERAPY FOR CANCER USING BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITORS
    Publication number: 20160279141
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 29, 2016
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
  • Compositions, Kits, and Methods for the Identification, Assessment, Prevention, and Therapy of Cancer
    Publication number: 20150004158
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 1, 2015
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub